Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization

D. S. Diaco, H. Hajarizadeh, C. R. Mueller, W. S. Fletcher, Rodney Pommier, E. A. Woltering

    Research output: Contribution to journalArticle

    88 Citations (Scopus)

    Abstract

    BACKGROUND: Overall survival and quality of life in patients with metastatic carcinoid tumors depend on control of tumor growth and suppression of amine-induced symptoms. METHODS: We report on a series of 10 patients with carcinoid tumors metastatic to the liver who were treated with long-term octreotide acetate therapy (100 to 500 μg three times a day), sequential intra-arterial 5-fluorouracil (5-FU) infusions, and hepatic tumor chemoembolization. RESULTS: All 10 patients remained asymptomatic or had extremely mild symptoms after combined modality therapy (mean follow-up duration of 51.5 months). Sixty percent of the patients had a >50% reduction of their tumor size (mean duration 42 months). An additional 30% experienced stabilization of tumor growth for 6 months or longer. Five of the 10 patients are currently alive. The mean group survival is 58 months since diagnosis (range 33 to 115) and 40 months since starting therapy (range 12 to 65). CONCLUSIONS: Combining octreotide acetate, intra-arterial 5-FU, and tumor chemoembolization effectively retards tumor growth while providing excellent symptom control.

    Original languageEnglish (US)
    Pages (from-to)523-528
    Number of pages6
    JournalAmerican Journal of Surgery
    Volume169
    Issue number5
    DOIs
    StatePublished - 1995

    Fingerprint

    Octreotide
    Carcinoid Tumor
    Drug Therapy
    Liver
    Neoplasms
    Fluorouracil
    Therapeutics
    Growth
    Combined Modality Therapy
    Survival
    Amines
    Quality of Life

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization. / Diaco, D. S.; Hajarizadeh, H.; Mueller, C. R.; Fletcher, W. S.; Pommier, Rodney; Woltering, E. A.

    In: American Journal of Surgery, Vol. 169, No. 5, 1995, p. 523-528.

    Research output: Contribution to journalArticle

    @article{ab3c33f65e454eda9a934cface75cb0b,
    title = "Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization",
    abstract = "BACKGROUND: Overall survival and quality of life in patients with metastatic carcinoid tumors depend on control of tumor growth and suppression of amine-induced symptoms. METHODS: We report on a series of 10 patients with carcinoid tumors metastatic to the liver who were treated with long-term octreotide acetate therapy (100 to 500 μg three times a day), sequential intra-arterial 5-fluorouracil (5-FU) infusions, and hepatic tumor chemoembolization. RESULTS: All 10 patients remained asymptomatic or had extremely mild symptoms after combined modality therapy (mean follow-up duration of 51.5 months). Sixty percent of the patients had a >50{\%} reduction of their tumor size (mean duration 42 months). An additional 30{\%} experienced stabilization of tumor growth for 6 months or longer. Five of the 10 patients are currently alive. The mean group survival is 58 months since diagnosis (range 33 to 115) and 40 months since starting therapy (range 12 to 65). CONCLUSIONS: Combining octreotide acetate, intra-arterial 5-FU, and tumor chemoembolization effectively retards tumor growth while providing excellent symptom control.",
    author = "Diaco, {D. S.} and H. Hajarizadeh and Mueller, {C. R.} and Fletcher, {W. S.} and Rodney Pommier and Woltering, {E. A.}",
    year = "1995",
    doi = "10.1016/S0002-9610(99)80210-4",
    language = "English (US)",
    volume = "169",
    pages = "523--528",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "5",

    }

    TY - JOUR

    T1 - Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization

    AU - Diaco, D. S.

    AU - Hajarizadeh, H.

    AU - Mueller, C. R.

    AU - Fletcher, W. S.

    AU - Pommier, Rodney

    AU - Woltering, E. A.

    PY - 1995

    Y1 - 1995

    N2 - BACKGROUND: Overall survival and quality of life in patients with metastatic carcinoid tumors depend on control of tumor growth and suppression of amine-induced symptoms. METHODS: We report on a series of 10 patients with carcinoid tumors metastatic to the liver who were treated with long-term octreotide acetate therapy (100 to 500 μg three times a day), sequential intra-arterial 5-fluorouracil (5-FU) infusions, and hepatic tumor chemoembolization. RESULTS: All 10 patients remained asymptomatic or had extremely mild symptoms after combined modality therapy (mean follow-up duration of 51.5 months). Sixty percent of the patients had a >50% reduction of their tumor size (mean duration 42 months). An additional 30% experienced stabilization of tumor growth for 6 months or longer. Five of the 10 patients are currently alive. The mean group survival is 58 months since diagnosis (range 33 to 115) and 40 months since starting therapy (range 12 to 65). CONCLUSIONS: Combining octreotide acetate, intra-arterial 5-FU, and tumor chemoembolization effectively retards tumor growth while providing excellent symptom control.

    AB - BACKGROUND: Overall survival and quality of life in patients with metastatic carcinoid tumors depend on control of tumor growth and suppression of amine-induced symptoms. METHODS: We report on a series of 10 patients with carcinoid tumors metastatic to the liver who were treated with long-term octreotide acetate therapy (100 to 500 μg three times a day), sequential intra-arterial 5-fluorouracil (5-FU) infusions, and hepatic tumor chemoembolization. RESULTS: All 10 patients remained asymptomatic or had extremely mild symptoms after combined modality therapy (mean follow-up duration of 51.5 months). Sixty percent of the patients had a >50% reduction of their tumor size (mean duration 42 months). An additional 30% experienced stabilization of tumor growth for 6 months or longer. Five of the 10 patients are currently alive. The mean group survival is 58 months since diagnosis (range 33 to 115) and 40 months since starting therapy (range 12 to 65). CONCLUSIONS: Combining octreotide acetate, intra-arterial 5-FU, and tumor chemoembolization effectively retards tumor growth while providing excellent symptom control.

    UR - http://www.scopus.com/inward/record.url?scp=0028943561&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0028943561&partnerID=8YFLogxK

    U2 - 10.1016/S0002-9610(99)80210-4

    DO - 10.1016/S0002-9610(99)80210-4

    M3 - Article

    C2 - 7747834

    AN - SCOPUS:0028943561

    VL - 169

    SP - 523

    EP - 528

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 5

    ER -